Neumora Therapeutics, Inc. (NMRA)Healthcare | Biotechnology | Watertown, United States | NasdaqGS
1.58 USD
-0.02
(-1.250%) ⇩
(July 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:39 a.m. EDT
Neumora Therapeutics is in freefall, driven by catastrophic operational failures and a looming legal crisis. The company recently scrapped a key depression drug after repeated late-stage trial failures, leading to significant layoffs and a sharp drop in share price. This fundamental deterioration is compounded by a formal securities fraud investigation launched by Levi & Korsinsky against the company's officers and directors, creating severe uncertainty about management integrity and future liabilities. Financially, the company is burning cash with negative free cash flow and no path to profitability, trading at a negative forward P/E. While the stock is technically cheap relative to its 52-week high, the combination of failed assets, mass layoffs, and active litigation makes it a dangerous speculative trap rather than a value opportunity. The options market confirms this pessimism, with traders loading up on deep out-of-the-money puts to bet on further declines or hedge existing positions, while call activity remains virtually non-existent. There is no dividend to provide income, and the business model appears fundamentally broken at this stage. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.105551 |
| AutoARIMA | 0.162326 |
| AutoETS | 0.162327 |
| MSTL | 0.172619 |
| MSTL_79 | 0.327638 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 19% |
| H-stat | 2.59 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 6.89 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 75.514 |
| Market Cap | 292,749,120 |
| Forward P/E | -2.04 |
| Beta | 2.77 |
| Website | https://www.neumoratx.com |
As of July 11, 2026, 4:39 a.m. EDT: Speculators are aggressively positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes $1.00 and $2.00) compared to negligible call volume. The put/call ratio is heavily skewed toward hedging or betting against the stock, while call activity is sparse and concentrated at distant strikes, indicating a lack of near-term bullish conviction.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.10344827 |
| Address1 | 260 Arsenal Place |
| Address2 | Suite 1 |
| All Time High | 21.0 |
| All Time Low | 0.611 |
| Ask | 2.03 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 1,214,840 |
| Average Daily Volume3 Month | 2,293,886 |
| Average Volume | 2,293,886 |
| Average Volume10Days | 1,214,840 |
| Beta | 2.773 |
| Bid | 1.16 |
| Bid Size | 2 |
| Book Value | 0.388 |
| City | Watertown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.58 |
| Current Ratio | 5.095 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.63 |
| Day Low | 1.57 |
| Debt To Equity | 75.514 |
| Display Name | Neumora Therapeutics |
| Earnings Call Timestamp End | 1,774,872,000 |
| Earnings Call Timestamp Start | 1,774,872,000 |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | -218,024,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.913 |
| Enterprise Value | 199,050,112 |
| Eps Current Year | -0.91993 |
| Eps Forward | -0.77417 |
| Eps Trailing Twelve Months | -1.3 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.7661 |
| Fifty Day Average Change | -0.1861 |
| Fifty Day Average Change Percent | -0.10537342 |
| Fifty Two Week Change Percent | 10.344828 |
| Fifty Two Week High | 3.65 |
| Fifty Two Week High Change | -2.0700002 |
| Fifty Two Week High Change Percent | -0.5671233 |
| Fifty Two Week Low | 0.83 |
| Fifty Two Week Low Change | 0.75000006 |
| Fifty Two Week Low Change Percent | 0.9036145 |
| Fifty Two Week Range | 0.83 - 3.65 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,694,698,200,000 |
| Float Shares | 113,847,904 |
| Forward Eps | -0.77417 |
| Forward P E | -2.0408955 |
| Free Cashflow | -108,301,128 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 92 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.23597 |
| Held Percent Institutions | 0.57882 |
| Implied Shares Outstanding | 185,284,244 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-09-15 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts. |
| Long Name | Neumora Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 292,749,120 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1684602478 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -222,394,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 296,454,790 |
| Number Of Analyst Opinions | 8 |
| Open | 1.59 |
| Operating Cashflow | -193,396,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 857 760 0900 |
| Previous Close | 1.6 |
| Price Eps Current Year | -1.717522 |
| Price Hint | 4 |
| Price To Book | 4.072165 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.884 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.01999998 |
| Regular Market Change Percent | -1.2499988 |
| Regular Market Day High | 1.63 |
| Regular Market Day Low | 1.57 |
| Regular Market Day Range | 1.57 - 1.63 |
| Regular Market Open | 1.59 |
| Regular Market Previous Close | 1.6 |
| Regular Market Price | 1.58 |
| Regular Market Time | 1,784,059,200 |
| Regular Market Volume | 771,862 |
| Return On Assets | -0.66388 |
| Return On Equity | -1.48737 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 185,284,244 |
| Shares Percent Shares Out | 0.0361 |
| Shares Short | 6,682,749 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 5,581,263 |
| Short Name | Neumora Therapeutics, Inc. |
| Short Percent Of Float | 0.0623 |
| Short Ratio | 1.63 |
| Source Interval | 15 |
| State | MA |
| Symbol | NMRA |
| Target High Price | 14.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 6.5325 |
| Target Median Price | 6.0 |
| Total Cash | 147,072,000 |
| Total Cash Per Share | 0.794 |
| Total Debt | 53,373,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.3 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.191525 |
| Two Hundred Day Average Change | -0.61152494 |
| Two Hundred Day Average Change Percent | -0.2790408 |
| Type Disp | Equity |
| Volume | 771,862 |
| Website | https://www.neumoratx.com |
| Zip | 2,472 |